The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Top Cited Papers
Open Access
- 3 April 2020
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 178, 104787
- https://doi.org/10.1016/j.antiviral.2020.104787
Abstract
No abstract availableKeywords
Funding Information
- National Breast Cancer Foundation Fellowship, Australia (ECF-17-007)
- NHMRC), Australia Senior Prinicple Research Fellow (APP1103050)
This publication has 30 references indexed in Scilit:
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirusJournal of Biological Chemistry, 2020
- Discovering drugs to treat coronavirus disease 2019 (COVID-19)Drug Discoveries & Therapeutics, 2020
- Anti-HCV, nucleotide inhibitors, repurposing against COVID-19Life Sciences, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trialThe Lancet Infectious Diseases, 2019
- Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP importScientific Reports, 2016
- Nuclear trafficking of proteins from RNA viruses: Potential target for antivirals?Antiviral Research, 2012
- The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-reviewThe AAPS Journal, 2008
- Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi MembraneJournal of Virology, 2007
- The Coronavirus Infectious Bronchitis Virus Nucleoprotein Localizes to the NucleolusJournal of Virology, 2001